Pipeline

Trustlife Therapeutics' pipeline features 14 proprietary drug candidates discovered using our advanced AI platform,Trustlife AI. Our end-to-end approach enables a seamless progression from target discovery through Hit Identification, extending through Clinical Phase-I studies.

Our approach combines the power of artificial intelligence with systems biological expertise, enabling us to accelerate the discovery and development of innovative therapeutics. By leveraging our proprietary AI platform, we can identify novel targets and optimize drug candidates more efficiently than traditional methods, bringing promising treatments to patients faster.

Our pipeline focuses on high-burden therapeutic areas including oncology (prostate, kidney, colon, lung, pancreatic, and breast cancers), neurodegeneration (Alzheimer's and Parkinson's), and muscle and inflammatory diseases. Several programs—such as those targeting prostate adenocarcinoma and muscle sarcopenia—have advanced to the preclinical PK/PD and toxicity evaluation stage.

Discovered through Trustlife AI and licensed by Trustlife Global, each candidate is the result of rigorous scientific validation and data-driven prioritization. The pipeline reflects our commitment to translating AI-enabled insights into first- and best-in-class therapies with the potential to transform patient care across complex and underserved indications.